CIDP

Neurology

17 drugs in development·5 companies·4 clinical trials

Drug Pipeline by Phase

Approved(6)

Drug	Company
cutaquig	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
cuvitru	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
gammagard liquid	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
hizentra	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
hyqvia	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
xembify	KORU Medical Systems Inc. Common Stock (DE) (KRMD)

Phase 3(10)

Drug	Company
gamunex-c	Grifols S.A. (GRFS)
hyqvia	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
hyqvia	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-411	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-411	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-771	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-771	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-881	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-881	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
xembify	Grifols S.A. (GRFS)

Phase 2(1)

Drug	Company
TAK-411	Merus N.V. (MRUS)

BioSniper tracks 17 drugs in development for CIDP across 5 companies.

There are 4 clinical trials targeting CIDP tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.